Li Yi, Cui Heng, Shen Dan-hua, Zhao Yan, Wei Li-hui, Qian He-nian
Department of Gynecologic Oncology Center, People's Hospital, Peking University, Beijing 100044, China.
Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):81-4.
To study the relationship between clinical pathological factors and prognosis.
Thirty-four cases with borderline ovarian tumors (BOT) and 30 cases with stage I ovarian epithelial cancer admitted in our hospital from Jan.1973 to Dec.2000 were studied retrospectively. All the cases were diagnosed according to the International Histological Classification and Staging of Ovarian Tumors (WHO, 1999).
Thirty-seven cases were finally diagnosed of BOT, 6 cases with "microinvasive" had been misinterpreted as stage I ovarian cancer and one had "non-invasive peritoneal implants". Serous (38%) and mucinous (51%) tumors were dominant type of BOT and 95% of tumors were at stage I (International Federation of Gynecology and Obstetrics, FIGO). All patients were operated, 11 cases given conservative surgery with a recurrence rate of 9%, 26 cases had adjuvant chemotherapy, cyclophosphamide + adriamycin + cis-platinum used mostly. 5-year and 10 year survival rates were both 100%. The prognosis of BOT is related to pathology and adjuvant therapy.
Surgery is the main treatment choice of BOT, and the criteria of chemotherapy must be adequately used.
研究临床病理因素与预后之间的关系。
回顾性研究1973年1月至2000年12月我院收治的34例卵巢交界性肿瘤（BOT）和30例Ⅰ期卵巢上皮癌患者。所有病例均根据《卵巢肿瘤国际组织学分类和分期》（世界卫生组织，1999年）进行诊断。
最终确诊为BOT的有37例，其中6例“微浸润”曾被误诊为Ⅰ期卵巢癌，1例有“非侵袭性腹膜种植”。浆液性（38%）和黏液性（51%）肿瘤是BOT的主要类型，95%的肿瘤处于Ⅰ期（国际妇产科联盟，FIGO）。所有患者均接受了手术，11例行保守手术，复发率为9%，26例行辅助化疗，主要使用环磷酰胺+阿霉素+顺铂。5年和10年生存率均为100%。BOT的预后与病理及辅助治疗有关。
手术是BOT的主要治疗选择，必须合理应用化疗标准。
Zotero 插件